Itoh T, Sakata Y, Suzuki H, Sugimoto N, Sohma N, Kishibe T, Higuchi S, Seino Y
Dept. of Internal Medicine, Misawa Municipal Hospital.
Gan To Kagaku Ryoho. 1992 Feb;19(2):241-4.
A 73-year-old man with diffuse large cell lymphoma was treated with noncross resistant alternating combination chemotherapy of CHOP and BEMP, consisting of cyclophosphamide (1,000 mg/body, i.v., day 1), doxorubicin (60 mg/body, i.v., day 1), vincristine (2 mg/body, i.v., day 1), prednisolone (100 mg/body, p.o., day 1-5), bleomycin (30 mg/body, i.v., day 22), etoposide (80 mg/body, i.v., day 22-24), mitoxantrone (6 mg/body, i.v., day 22), and procarbazine (100 mg/body, p.o., day 22-26). Following the three courses' administration of CHOP and BEMP, complete remission was obtained with a remission duration of over ten months. Leukocytopenia was a dose-limiting factor. It is concluded that noncross resistant alternating combination chemotherapy of CHOP and BEMP is effective for diffuse large cell lymphoma.
一名73岁弥漫性大细胞淋巴瘤男性患者接受了CHOP和BEMP的非交叉耐药交替联合化疗，CHOP方案包括环磷酰胺（1000mg/体，静脉注射，第1天）、多柔比星（60mg/体，静脉注射，第1天）、长春新碱（2mg/体，静脉注射，第1天）、泼尼松龙（100mg/体，口服，第1 - 5天），BEMP方案包括博来霉素（30mg/体，静脉注射，第22天）、依托泊苷（80mg/体，静脉注射，第22 - 24天）、米托蒽醌（6mg/体，静脉注射，第22天）和丙卡巴肼（100mg/体，口服，第22 - 26天）。在进行三个疗程的CHOP和BEMP治疗后，获得了完全缓解，缓解期超过十个月。白细胞减少是剂量限制因素。结论是CHOP和BEMP的非交叉耐药交替联合化疗对弥漫性大细胞淋巴瘤有效。
